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Allergic disorders commonly involve both chronic tissue inﬂammation and remodeling caused by
immunological reactions to various antigens on tissue surfaces. Due to their anatomical location, vascular
endothelial cells are the ﬁnal responders to interact with various exogenous factors that come into
contact with the epithelial surface, such as pathogen-associated molecular patterns (PAMPs) and anti-
gens. Recent studies have shed light on the important roles of endothelial cells in the development and
exacerbation of allergic disorders. For instance, endothelial cells have the greatest potential to produce
several key molecules that are deeply involved in allergic inﬂammation, such as periostin and thymus
and activation-regulated chemokine (TARC/CCL17). Additionally, endothelial cells were recently shown to
be important functional targets for IL-33dan essential regulator of allergic inﬂammation. Notably,
almost all endothelial cell responses and functions involved in allergic inﬂammation are not suppressed
by corticosteroids. These corticosteroid-refractory endothelial cell responses and functions include TNF-
a-associated angiogenesis, leukocyte adhesion, IL-33-mediated responses and periostin and TARC pro-
duction. Therefore, these unique responses and functions of endothelial cells may be critically involved in
the pathogenesis of various allergic disorders, especially their refractory processes. Here, we review
recent studies, including ours, which have elucidated previously unknown pathophysiological roles of
vascular endothelial cells in allergic inﬂammation and discuss the possibility of endothelium-targeted
therapy for allergic disorders.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The global prevalence of allergic disorders, including a range of
chronic illnesses, such as bronchial asthma (BA),1 allergic rhinitis,2
eosinophilic gastrointestinal disorders3 and atopic dermatitisand Immunology, National
, 2-10-1 Okura, Setagaya-ku,
ety of Allergology.
rgology. Production and hosting by Else(AD),4 has been increasing in recent decades, leading to serious
social and economic burdens.5 The pathogenesis of these allergic
disorders commonly involves both chronic tissue inﬂammation and
remodeling.6
The pathogenesis of allergic diseases is characterized by
chronically progressive inﬂammatory reactions that are often
triggered by exposure of epithelial surfaces to antigens. Epithelial
inﬂammation leads to responses by tissue structural cells, in
addition to activation of a variety of immune cells such as lym-
phocytes, phagocytes and granulocytes, to the antigens that play
essential roles in the pathogenesis of the inﬂammation. Amongvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
T. Shoda et al. / Allergology International 65 (2016) 21e2922tissue structural cells, epithelial cells constitute the initial struc-
tural and immunological barrier to entry of foreign antigens. In
addition, recent studies strongly suggest that epithelial cells also
function as important sources of a wide variety of immune medi-
ators. In particular, novel epithelial cell-derived cytokines,
including IL-25, IL-33 and thymic stromal lymphopoietin (TSLP),
have attracted considerable interest because of their potent func-
tions in promoting type 2 immunity.7 Fibroblasts, another type of
tissue structural cell, play crucial roles in maintaining tissue ho-
meostasis and bringing about wound healing under normal con-
ditions. However, excessive and chronic inﬂammation as a
consequence of activation of immune responses often leads to
irreversible tissue ﬁbrosis, resulting in severe and refractory ill-
nesses.8 Compared to epithelial cells and ﬁbroblasts, the roles of
vascular endothelial cells in allergic disorders remain poorly un-
derstood. Figure 1A shows a simpliﬁed structure of the tissue
surface.
Endothelial cells form a one-cell-thick layer called the endo-
thelium (Fig. 1A), which lines the inner wall of blood vessels,
forming a selectively permeable barrier between the blood inside
the vessels and the surrounding tissues. The endothelium is a
highly specialized structure spread throughout the body. It has
many vital functions, including blood and oxygen supply, nutrient
delivery, metabolic homeostasis and immune cell trafﬁcking.9e13
On the other hand, we have elucidated several critical roles of
pulmonary and skin microvascular endothelial cells in allergic
inﬂammation. In particular, endothelial cells have the greatest po-
tential to produce several key molecules involved in allergic
inﬂammation. The blood levels of periostin14 and thymus and
activation-regulated chemokine (TARC/CCL17)15 already serve as
reliable biomarkers reﬂecting disease progression of allergic dis-
orders. In addition to being key cellular sources of molecules
essential for allergic inﬂammation, endothelial cells are important
functional targets for IL-33,16 whose gene locus has been reported
to be the most consistently associated with BA in all tested ethnic
groups. Notably, almost all endothelial cell responses and functions
involved in allergic inﬂammation cannot be suppressed by corti-
costeroid treatment, a current ﬁrst-line therapy for various allergicFig. 1. The basic biology of vascular endothelial cells. (A) Simpliﬁed structure of the tissue su
functions. The different roles of endothelial cells are illustrated in non-inﬂamed conditionsdisorders. We, therefore, inferred that endothelial cell responses
and functions are crucially involved in the progression of various
allergic disorders, especially in corticosteroid-refractory processes.
This review article focuses on the contributions of vascular
endothelial cells in the development and exacerbation of allergic
disorders. Following a brief introduction of the basic biology, we
will review how recent reports, including ours, have elucidated the
responses of endothelial cells to representative type 2 cytokines
and chemokines in allergic airway and skin inﬂammation. We
ﬁnally discuss the roles of endothelial cells in corticosteroid
refractoriness and the possibility of endothelium-targeted therapy
for allergic disorders.
Structure and fundamental functions of endothelial cells
Blood vessels are composed of a sheet of inner endothelium,
which is a monolayer of endothelial cells that surrounds functional
cells, including pericytes and vascular smooth muscle cells, and
extracellular matrix (Fig. 1A).17 The endothelial and supportive
mural cells are tightly bound to each other, partly through integ-
rins, thereby maintaining vascular integrity (Fig. 1A). The endo-
thelium is composed of 1e6  1013 endothelial cells that cover
more than 1000 m2 of surface area throughout the body.9,10
In the absence of inﬂammation, vascular endothelial cells serve
as an essential barrier between the bloodstream and vessel walls. In
addition to being a physical barrier, endothelial cells have various
indispensable functions, which can be classiﬁed into three major
groups: 1)modulation of metabolic homeostasis (trophic action), 2)
control of vascular hemodynamics (tonic action) and 3) regulation
of vascular permeability, coagulation and cell extravasation
(trafﬁcking).18
These functions of endothelial cells change during the transition
from quiescent to inﬂammatory conditions. The initial change of
the vessels in acute inﬂammation is characterized by increased
blood ﬂow secondary to arteriolar and capillary bed dilation (ery-
thema and warmth).19,20 Increased vascular permeability, as a
consequence of either widening of interendothelial cell junctions of
the venules or direct endothelial cell injury, results in an exudate ofrface. In addition to being a physical barrier, endothelial cells have several indispensable
(B) and in inﬂammation (C).
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cells normally maintain a balance between the pro- and anti-
coagulant activities, but they express numerous pro-coagulant
factors in response to injury or inﬂammatory cytokines. Endothe-
lial injury exposes the underlying subendothelial von Willebrand
factor and basement membrane collagen, stimulating platelet
adhesion, platelet activation and aggregation. These interactions of
platelets and endothelium have a profound impact on clot forma-
tion as a defense mechanism. Concurrently, leukocyte recruitment
from the bloodstream into the extravascular tissue at sites of
pathogen invasion or tissue damage is a multi-step process: 1)
loose attachment to and roll-over on the endothelium (mediated by
selectins and carbohydrates on endothelial cells), 2) ﬁrm and se-
lective attachment to the endothelium (mediated by integrins and
chemokines), 3) migration through interendothelial spaces and 4)
detachment from the blood vessel.23e25 Thus, these structural and
functional changes of endothelial cells facilitate leukocyte recruit-
ment and alter gene expression proﬁles in inﬂammatory conditions
and are collectively called “endothelial activation”.26
Roles of endothelial cells in allergic inﬂammation
The roles of endothelial cells in innate and adaptive immune
responses
Allergic disorders commonly involve both chronic tissue
inﬂammation and remodeling caused by immunological reactions
to various pathogen-associated molecular patterns (PAMPs) and/or
endogenous danger substances released from damaged tissues, i.e.,
so-called alarmins. Due to their anatomical location, vascular
endothelial cells are the ﬁnal responders to interact with various
alarmins on the epithelial surface. Endothelial cells, as well as
epithelial cells, actively participate in both innate and adaptive
immune responses, which are crucially involved in the pathogen-
esis of allergic disorders.27,28
The primary inﬂammatory response of tissue cells is initiated by
recognition of various PAMPs and alarmins via pattern-recognition
receptors (PRRs); this is called innate immunity. Indeed, vascular
endothelial cells spontaneously express class I major histocom-
patibility complex (MHC) molecules and a wide variety of func-
tional PRRs, including Toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain-like receptors (NLRs), as
reviewed by Danese et al.,29 as well as various cytokine and che-
mokine receptors (Fig. 1B).30,31 Endothelial cells are also capable of
secreting a broad spectrum of cytokines and chemokines in
response to stimulation. As a result, endothelial cells participate in
the immune response and rapidly produce various inﬂammatory
molecules (e.g., IL-1a, IL-1b, IL-6, IL-8, TNF-a, etc.)32,33 that are
important for endothelial activation (Fig. 1C). Concurrently, endo-
thelial cells can also produce anti-inﬂammatory cytokines and
chemokines that prevent progression of the inﬂammatory
cascade.34 The inﬂammatory mediators involved in those inﬂam-
matory cascades or released by endothelial cells were reviewed and
discussed in depth in a recent review article by Mai et al.28
In addition, in response to some inﬂammatory stimuli, endo-
thelial cells express class II MHCmolecules that present endothelial
antigens to immune cells, leading to long-lasting and highly spe-
ciﬁc protection, known as adaptive immunity (Fig. 1C).35e37 Thus,
vascular endothelial cells play pivotal roles in both innate and
adaptive immune responses.
Cascade of allergic inﬂammation regulated by structural cells
Allergic inﬂammation is regulated by complex interactions
among several inﬂammatory and structural cells via inﬂammatorymediators.1 A wide variety of mediators, cytokines and chemokines
exertingmany different effects on the airways and skin are known to
be involved in the pathology of allergic disorders, maintaining
chronic allergic inﬂammation. A well-known cascade of these net-
works in allergic inﬂammation is characterized by a type 2 immune
response with production of speciﬁc cytokines and chemokines
initiated by allergen exposure.38 In addition to acute responses,
cytokines and chemokines produced by Th2 cells, mast cells and
basophils recruit eosinophils from the blood into the airways and
skin, leading to allergic asthma and atopic dermatitis. As noted
earlier, besides hematopoietic cells, structural cells such as epithelial
cells, ﬁbroblasts and smoothmuscle cells are known to contribute to
allergic inﬂammation. Nevertheless, the roles of vascular endothe-
lial cells in allergic inﬂammation had not yet been well studied.
Endothelial cells in the lung
Airway remodeling and angiogenesis
Bronchial asthma (BA) is a chronic inﬂammatory disease of the
airways that is characterized by airway hyperresponsiveness,
episodic airway obstruction and a decline in lung function. In some
patients with BA, chronic pulmonary inﬂammation results in
persistent structural changes in the airway walls, including goblet
cell hyperplasia, shedding of epithelial cells, thickening of the
basement membrane, extracellular matrix deposition and ﬁbrosis,
smooth muscle cell hypertrophy/hyperplasia and accelerated
angiogenesis.39 These structural changes are collectively called
“airway remodeling”, which is thought to lead to irreversible
airway obstruction and exacerbation of BA. Angiogenesis is a
complicated, multiphase process regulated by several factors,
including molecules closely related with the pathogenesis of
asthma.40e42 Previous studies have suggested that, among the
above changes underlying airway remodeling, accelerated angio-
genesis occurs even in the early stage of chronic BA43 but is not seen
in the airway wall in chronic obstructive pulmonary disease
(COPD), another pulmonary chronic inﬂammatory disease.43 Thus,
angiogenesis, the growth of new vessels from existing ones, is one
of the most important pathological features of BA.
Vascular endothelial growth factor (VEGF), an endothelial cell-
speciﬁc mitogen essential for angiogenesis,44 has been reported
to be critically involved in angiogenesis in the asthmatic airway. For
instance, VEGF is abundant in asthmatic airways compared to
healthy control airways.45e47 Notably, VEGF levels in the airways
show a positive correlation with the severity of airway inﬂamma-
tion48 and are associated inversely with lung function,49 suggesting
that VEGF plays important roles in BA disease progression. On the
other hand, a number of reports demonstrated that inhaled corti-
costeroid (ICS) treatment effectively inhibited VEGF over-
production in the airways, resulting in reduced pulmonary
angiogenesis and improved lung function, especially in mild asth-
matic patients.50e52 Importantly, however, some patients with se-
vere BA often exhibit increased pulmonary angiogenesis regardless
of long-term treatment with corticosteroids. These pathological
ﬁndings suggest that increased pulmonary angiogenesis, especially
in severe BA, may be poorly responsive to corticosteroid therapy
and clinically associated with reduced lung function. Therefore,
factor(s) other than VEGF may be involved in the corticosteroid-
refractory angiogenesis in severe BA.
Both elevated levels of TNF-a and neutrophilic inﬂammation in
the airway are reported to be characteristic features in some pa-
tients with severe asthma.53e55 We previously showed that type 2
cytokines such as IL-4 or IL-13, but not type 1 cytokines such as IFN-
g, signiﬁcantly promoted in vitro angiogenesis by human pulmo-
nary microvascular endothelial cells, but only in the co-presence of
TNF-a.56 Importantly, the TNF-a- and type 2 cytokine-mediated
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chemokines, including IL-8, growth-related oncogene (GRO),
epithelial neutrophil-activating peptide 78 (ENA78) and gran-
ulocyte chemotactic protein 2 (GCP-2). It should be noted that the
CXCR2 chemokines can act not only as potent neutrophilic che-
moattractants mediated via CXCR2 receptors on neutrophils, but
also as potent angiogenic factors mediated via CXCR2 receptors on
microvascular endothelial cells.57,58 Thus, the increased airway
angiogenesis as well as neutrophilic inﬂammation in corticosteroid
refractory severe asthma might be primarily due to TNF-a and
CXCR2 chemokines, rather than mediation by VEGF. In fact, both IL-
8 and TNF-a are reported to be abundant in severe asthmatic
airways.53,54,59,60
Endothelial cells and IL-33
Complex interactions between environmental factors and ge-
netic variants are at the heart of the pathogenesis of BA. To date, a
number of studies investigated the genetics of BA. Several recent
large-scale genome-wide association studies (GWAS) found that
both IL33 and its receptor, IL1RL1/ST2dwhich are located on
different chromosomesdare the most consistently associated
genes for asthma, regardless of race differences.61e63 IL-33, a
member of the IL-1 family of cytokines, is a tissue-derived factor
and may be involved in type 2 immunity. Although IL-33 was
originally identiﬁed as nuclear factor from high-endothelial ve-
nules (NF-HEV),64 subsequent studies revealed that it is constitu-
tively expressed in the nucleus of such tissue cells as epithelial and
endothelial cells and is released as an alarmin by damaged tissue
cells after injury and/or trauma.65 The target cells of IL-33 express
IL-33 receptors66 and include various effector cells such as group 2
innate lymphoid cells (ILC2),67,68 Th2 cells,69 eosinophils,70 baso-
phils,71,72 dendritic cells73 and mast cells.74 These effector cells
abundantly produce type 2 cytokines such as IL-5 and IL-13 upon
IL-33 stimulation. In addition, upon exposure to IL-33, dendritic
cells are activated and facilitate naïve T cell development towards
atypical Th2 cells which produce IL-5 and IL-13 but almost no IL-4.
We reported that IL-33 can stimulate pulmonary microvascular
endothelial and epithelial cells via the IL1RL1/ST2 receptor, and
those cells then immediately and strongly produce CXCR2 che-
mokines, including IL-8.16 Those ﬁndings suggest that such tissue
structural cells as epithelial and endothelial cells play roles not only
as signiﬁcant sources of IL-33, but also as important functional
targets of IL-33. IL-13 as well as IL-4 signiﬁcantly enhanced IL1RL1/
ST2 expression and function in both epithelial and endothelial cells
in a signal transducer and activator of transcription 6 (STAT6)-
dependent manner.16 These observations suggest that allergic in-
dividuals, who have type 2-skewed immunity, might be more
sensitive to IL-33-mediated inﬂammatory responses by tissue cells
than non-allergic individuals.
As described above, CXCR2 chemokines, such as IL-8, are
indispensable for pulmonary angiogenesis.56 Since IL-33 can pro-
mote strong CXCR2 chemokine production by pulmonary endo-
thelial and epithelial cells,16 IL-33 might be involved in pulmonary
angiogenesis. In fact, a recent report demonstrated that IL-33 pro-
motes angiogenesis and vascular permeability by stimulating
endothelial nitric oxide production via the IL1RL1/ST2 receptor.75
Taken together, IL-33, a potent type 2-promoting cytokine, can
act directly on pulmonary tissue cells and is crucially involved in
airway remodeling, including angiogenesis.
Endothelial cells in the skin
The skin and allergy
The skin is the largest organ of the human body, and recent evi-
dence has begun to highlight the critical role of the skin in thepathogenesis ofmultiple allergic disorders, in addition to its primary
function as a structural barrier.76 In fact, we recently reported that
daily application of amoisturizer to neonateswith a family history of
allergic disorders during the ﬁrst 32 weeks of life can signiﬁcantly
reduce the risk of AD/eczema.77 These observations suggest that skin
barrier function is directly involved in the development of AD. The
skin is structurally composed of two different layers, the epidermis
and dermis. Whereas the epidermis is an avascular layer of stratiﬁed
squamous epithelium, the dermis is highly vascularized and
composed largely of extracellular matrix components. The dermal
vasculature is organized into a deep and a superﬁcial horizontal
plexus, and it might play a distinct role in skin allergy.
Endothelial cells in atopic dermatitis; involvement of thymus and
activation-regulated chemokine (TARC/CCL17)
Atopic dermatitis (AD) is characterized by chronic or relapsing
eczematous lesions and recurrent pruritus.78 AD lesions are criti-
cally associated with activated vascular endothelial cells, and the
cutaneous vasculature thus plays key roles in various clinical
symptoms of AD, including erythema, edema, effector cell recruit-
ment and white dermographism. Various effector cells, including
lymphocytes, phagocytes and granulocytes, communicate closely
with the endothelium and activate each other via paracrine stim-
ulation of inﬂammatory mediators. Furthermore, adhesion, teth-
ering and transmigration of inﬁltrating effector cells are also highly
regulated, active communication processes between endothelial
cells and those effector cells. Thus, speciﬁc interactions between
activated endothelial and effector cells are essentially involved in
the establishment and progression of AD pathology.
Thymus and activation-regulated chemokine (TARC/CCL17), a
member of the CC chemokine family, is a potent and selective
chemoattractant for Th2 cells via CC chemokine receptor 4
(CCR4).79 There is increasing evidence that TARC is involved in the
development of various allergic disorders, and elevated TARC blood
levels were especially seen in AD patients.80,81 Importantly, serum
TARC levels already serve as a reliable biomarker reﬂecting disease
progression of AD in daily clinical practice, especially in Japan.82
However, the reason that serum TARC levels correlate well with
the degree of AD progression remains unclear. Although physicians
traditionally check the condition of skin to determine whether a
particular treatment has been successful or not, visual examination
results may not always be accurate and reliable. This inaccuracy
might be due to the existence of subclinical dermal inﬂammation,
which is often associated with severe and corticosteroid-refractory
AD.15 In fact, it is well known that AD patients with elevated serum
TARC levels tend to relapse easily and fail to achieve good control of
AD symptoms, evenwhen their skin lesions seem to disappear after
initial anti-inﬂammatory therapy.
These observations indicate that serum TARC levels in AD pa-
tients correlate well with the degree of subclinical inﬂammation in
the skin. Therefore, we hypothesized that dermal cells may be
major cellular sources of TARC in AD patients and may play crucial
roles in subclinical inﬂammation in the AD skin. Indeed, we
recently demonstrated that both dermal microvascular endothelial
cells and ﬁbroblasts, but not epidermal keratinocytes, possess vast
potential to produce TARC protein in response to TNF-a plus IL-4 or
IL-13.83 Anti-TARC mAb reacted speciﬁcally with microvascular
endothelial cells of the dermis, but not with epidermal cells, at sites
of CCR4þ-T cell accumulation in inﬂamed AD skin,84,85 further
suggesting that TARC derived from endothelial cells may be func-
tionally associated with the pathophysiology of AD.86 Taken
together, complete inhibition of inﬂammation in the dermis is
thought to be particularly important for suppressing not only the
TARC blood level, but also progression of AD, even if epidermal
eczematous lesions seem to be improved.
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refractoriness of allergic disorders
Corticosteroids are currently the most effective anti-
inﬂammatory agents for treating allergic disorders, including
BA87 and AD.82 However, the therapeutic response to corticoste-
roids varies among individuals and with the disease sub-
phenotype, and the mechanisms underlying corticosteroid refrac-
toriness remain obscure. We examined the effectiveness of corti-
costeroids on various tissue cells involved in allergic disorders and
found cell- and stimulant-dependent effects. In particular, the
impact of corticosteroids on microvascular endothelial cells is
apparently distinct from that on other airway and skin structural
cells, including epithelial cells, smooth muscle cells and ﬁbro-
blasts.88 We therefore surmise that microvascular inﬂammation in
allergic disorders may be very important to corticosteroid
refractoriness.
Corticosteroid-refractory angiogenesis
As described in an earlier section (Airway remodeling and
angiogenesis), VEGF-dependent pulmonary angiogenesis, especially
in mild BA patients or in vitro experiments, tends to be highly
responsive to corticosteroid therapy, whereas severe BA patients
often exhibit increased pulmonary angiogenesis in spite of long-
term corticosteroid treatment. We demonstrated that, only in the
presence of TNF-a, type 2 cytokines such as IL-4 and IL-13 signiﬁ-
cantly promoted in vitro pulmonary angiogenesis through auto-
crine stimulation of CXCR2 chemokines, including IL-8.56
Importantly, CXCR2-regulated angiogenesis was not inhibited by
corticosteroid treatment, because corticosteroids have little effect
on TNF-a-induced CXCR2 chemokine production by human pul-
monary microvascular endothelial cells.88,89 These observations
further support the notion that TNF-a/CXCR2 chemokine-regulated
corticosteroid-refractory angiogenesis might be crucially involved
in the progression of severe BA.
Corticosteroid effects on leukocyte adhesion to endothelial cells
Although such phenotypic changes in severe asthma as
increased TNF-a and neutrophilic inﬂammation are thought to
contribute to corticosteroid refractoriness,90 the underlying
mechanisms of acquisition of corticosteroid refractoriness are not
fully understood. Once tissue cells recognize PAMPs or alarmins,
multiple pro-inﬂammatory molecules that are necessary for
leukocyte recruitment into inﬂamed tissues act on the vascular
endothelium. This recruitment is an important step in the devel-
opment of acute and chronic inﬂammatory responses91 and is a
dynamic process requiring mutual interactions between leukocytes
and the activated vascular endothelium. TNF-a is the most promi-
nent factor in vascular endothelium activation. To that end, TNF-a
can induce expression of various molecules on the vascular endo-
thelium that are essential for leukocyte recruitment into inﬂamed
tissues, including intercellular adhesion molecule 1 (ICAM-1) and
vascular cell adhesion molecule 1 (VCAM-1).92
We demonstrated that TNF-a-induced expression of ICAM-1
and VCAM-1 on human pulmonary microvascular endothelial
cells was further enhanced by corticosteroid treatment, via its re-
ceptors.89 The corticosteroid treatment also enhanced in vitro
adhesion of neutrophils and eosinophils to the TNF-a-treated
endothelial cells.89 These observations may explain, at least in part,
corticosteroid refractoriness that is seen especially in severe
asthma, which is characterized by markedly elevated TNF-a pro-
duction. In agreement with our ﬁndings, the total number of ves-
sels expressing ICAM-1 was signiﬁcantly higher in severecorticosteroid-dependent asthmatic airways than in mild asth-
matics and control subjects.93 In contrast, TNF-a-induced ICAM-1
expression by airway epithelial and smooth muscle cells was
effectively inhibited by corticosteroid treatment (our unpublished
data). Therefore, the side effects of corticosteroid might be seen as
speciﬁc features of microvessels in the airway, but the underlying
molecular mechanism for such in vitro observations still needs to be
elucidated.Corticosteroid actions on IL-33-mediated responses of endothelial
and epithelial cells
As described in an earlier section (Endothelial cells and IL-33), IL-
33, a potent type 2-promoting cytokine, can induce production of
CXCR2 chemokines (such as IL-8) that are major neutrophil che-
moattractants as well as pro-angiogenic factors, by both pulmonary
microvascular and epithelial cells. We also found that IL-33-
induced IL-8 production by epithelial cells was almost completely
abolished by corticosteroid treatment. In contrast, that same
response in microvascular endothelial cells was only partially
abolished by corticosteroid.16 These ﬁndings further suggest that
the poor effect of corticosteroids on TNF-a- and IL-33-mediated
inﬂammatory responses of microvascular endothelial cells,
including corticosteroid-refractory angiogenesis, might be crucially
involved in the refractoriness seen in asthmatics.Cell type-dependent effects of corticosteroid on periostin production
Periostin is a matricellular protein originally isolated from an
osteoblast cell line.94 This molecule has recently received much
attention in the ﬁeld of allergy research because of its pivotal role in
the chronicity of allergic inﬂammation as a component of
corticosteroid-refractory tissue ﬁbrosis.14,95,96 Furthermore, serum
periostin levels serve as a systemic biomarker reﬂecting develop-
ment of airﬂow limitation97 and airway eosinophilic inﬂamma-
tion,98 even in asthmatic patients receiving high doses of
corticosteroid treatment. Therefore, we hypothesized that there
must be an important cellular source of periostin in a
corticosteroid-refractory manner. In agreement with other studies,
we found that IL-4, IL-13 and TGF-b each induced considerable
amounts of periostin protein production by ﬁbroblasts derived
from both lung and skin.99 Of note, corticosteroid treatment
completely inhibited IL-4/IL-13-induced, but did not affect TGF-b-
induced, periostin production by ﬁbroblasts. Microvascular endo-
thelial cells from lung and skin showed similar periostin induction
proﬁles as ﬁbroblasts when treated with IL-4/IL-13 but not with
TGF-b. Remarkably, corticosteroid treatment of microvascular
endothelial cells further enhanced, rather than reduced, their IL-4/
IL-13-induced periostin production.99 These observations suggest
that microvascular endothelial cells, along with ﬁbroblasts, are
likely to be signiﬁcant cellular sources of periostin. Overproduction
of periostin despite adequate corticosteroid therapy might be due
to corticosteroid refractoriness to periostin production by micro-
vessels, leading to chronic corticosteroid-refractory tissue ﬁbrosis
in the lung and/or skin. Like periostin, TARC production by micro-
vascular endothelial cells derived from skin was further enhanced
by corticosteroid treatment.83 Interestingly, unlike periostin, TARC
production by skin ﬁbroblasts was synergistically enhanced by
corticosteroid treatment. Clariﬁcation of the molecular mecha-
nisms underlying such cell-type-dependent and molecular-speciﬁc
effects of corticosteroids may help us better understand the re-
fractory processes in allergic disorders and aid in the development
of speciﬁc therapeutic strategies for severe corticosteroid-
refractory allergic disorders.
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corticosteroid-refractory allergic disorders
The unique and various effects of corticosteroids on endothelial
cells, compared with on other tissue structural cells such as
epithelial cells and ﬁbroblasts, may be critically involved in re-
fractory allergic disorders. Likewise, these observations also sug-
gest that endothelial-targeted therapies are likely to become
important treatment options for corticosteroid-refractory allergies.
For instance, CXCR2 seems to be a potential therapeutic target for
attenuating corticosteroid-refractory angiogenesis in the lung, as
well as attenuating CXCR2 chemokine-induced neutrophil
recruitment and activation, especially in patients with severe
asthma, characterized by elevated levels of TNF-a and neutrophilic
inﬂammation.55 ICAM-1, an adhesion molecule for neutrophils, on
microvessels is also a potential target for preventing neutrophil
recruitment in local tissues, because ICAM-1-expressing vessels
were reported to be increased in the severe corticosteroid-
dependent asthmatic airway.93 IL-33 and its receptor, IL1RL1/ST2,
which are the genes most consistently associated with BA onset,
can act on various potent effector cells, including ILC2 and micro-
vascular endothelial cells. Thus, targeting the IL-33-IL1RL1/ST2 axis
may be effective not only for curing BA symptoms but also for
preventing the onset of BA.
Unique genes in endothelial cells
As described in an earlier section (Airway remodeling and
angiogenesis), TNF-a and IL-4 synergistically promoted
corticosteroid-refractory angiogenesis of pulmonary microvascular
endothelial cells through autocrine stimulation of CXCR2 chemo-
kines.56 These results suggest that the responses of endothelial cells
to combined stimulation with TNF-a and IL-4 might be crucial for
exacerbation of BA. We therefore performed comprehensive geneFig. 2. The possible roles of endothelial cells in allergic airway inﬂammation. Schematic s
described in this review article.expression proﬁling of microvascular endothelial cells in response
to TNF-a plus IL-4 stimulation in order to explore new pathways
and/or factors involved in the development of more severe BA. We
unexpectedly found that a gene unfamiliar to us, pro-melanin-
concentrating hormone (PMCH), which encodes an appetite-
stimulating peptide, was by far the most strongly induced gene
(over 1200-fold increase), in a STAT6-dependent manner.100 PMCH
was inhibited by corticosteroid treatment (our unpublished data)
even though PMCH is an endothelial cell-speciﬁc transcript (Fig. 2
left panel). These results indicate that responses of endothelial
cells can potentially be down-regulated by corticosteroids.
Melanin-concentrating hormone (MCH) is a cyclic, 19-amino-
acid polypeptide that was originally isolated from the pituitary of
teleost ﬁsh and found to lighten skin color by regulating melano-
some aggregation.101 In mammals, the MCH system appears to be
essential for regulation of feeding behavior, energy homeostasis
and anxiety-related responses.102,103 Indeed, mice lacking the
PMCH gene had a lean phenotype as a consequence of decreased
appetite and increased metabolic rate.104 Furthermore, MCH
receptor-knockout mice showed reduced anxiety-like behavior105
as well as a lean phenotype and resistance to diet-induced
obesity.106
On the other hand, the major sources and physiological roles of
MCH in the periphery remain unknown. We showed that human
vascular endothelial cells from different parts of the body
commonly produce considerable amounts of MCH peptide in
response to such type 2 cytokines as IL-4 and IL-13, irrespective of
their origin, and the production is transcriptionally regulated via
STAT6.100 Importantly, Sandig et al.107 demonstrated that human
Th2 cells, but not Th1 cells, can also selectively produce MCH,
suggesting that type 2 inﬂammation might be associated with
obesity and/or depression. Of note, epidemiologic studies found
that allergy correlated positively with obesity108 and depression.109
Allergic disorders, obesity and depression, all of which areummary of the possible roles of endothelial cells in allergic airway inﬂammation, as
Fig. 3. The possible roles of endothelial cells in allergic skin inﬂammation. Schematic summary of the possible roles of endothelial cells in allergic skin inﬂammation, as described in
this review article.
T. Shoda et al. / Allergology International 65 (2016) 21e29 27representative modern diseases, are considered to be very impor-
tant worldwide public health issues. We anticipate future studies
that will explore our hypothesis that MCH plays a central role in the
mechanistic link between allergic inﬂammation and obesity or
depression.Conclusions
Recent studies have shed light on the importance of endothelial
cells in the development and exacerbation of allergic disorders.
Figure 2, 3 present schematic summaries of the known and putative
roles of endothelial cells that have been described in this review
article. These cells produce several key molecules involved in
allergic disorders, such as periostin and TARC, which are not only
critical to the pathogenesis of the disorders but also already serve
as reliable biomarkers reﬂecting disease progression. Furthermore,
among tissue structural cells, endothelial cells are the most sig-
niﬁcant functional targets for IL-33, which is a key regulator of
allergic inﬂammation. Most importantly, almost all endothelial cell
responses and functions relevant to allergic inﬂammation are not
inhibited by corticosteroid treatment, a current ﬁrst-line therapy
for various allergic disorders. Corticosteroid-refractory endothelial
cell responses and functions include TNF-a-associated angiogen-
esis, leukocyte adhesion, IL-33-mediated responses and periostin
and TARC production. Therefore, these unique and varied
corticosteroid-refractory responses and functions seem likely to be
critically involved in the refractory processes of allergic disorders,
and endothelial-targeted therapies may become important treat-
ment options for corticosteroid-refractory allergic disorders.
Moreover, a complete mechanistic understanding of how endo-
thelial cells contribute to chronicity of allergic inﬂammation
promises to provide new insights into the pathogenesis of severe
allergic disorders as well as novel diagnostic and therapeuticapproaches. Interestingly, in response to TNF-a plus IL-4 stimula-
tion, the endothelial cell transcriptome showed marked up-
regulation of PMCH, which plays central roles in regulating
feeding behavior, energy homeostasis and anxiety-related re-
sponses. MCH may be a key molecule linking allergy to obesity and
depression, correlations that have already been shown epidemio-
logically. Thus, endothelial cell biology is an exciting and potentially
high-reward research ﬁeld in regard to allergies.Acknowledgments
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